Allogene Therapeutics Reports First Clinical Data from Phase 1 RESOLUTION Study of ALLO-329 in Autoimmune Disease

Allogene Therapeutics announced preliminary Phase 1 data from the RESOLUTION study of ALLO-329, an allogeneic CAR T therapy for autoimmune diseases. The trial showed a favorable safety profile with no dose-limiting toxicities, ICANS, GvHD, or Grade ≥3 CRS events in 18 patients. In 10 patients with systemic sclerosis, 8 achieved clinically meaningful improvements in skin scores across all lymphodepletion approaches, including without lymphodepletion, with 9 remaining off immunosuppressive therapy.